“MCAS Symptoms: Recognizing Mast Cell Activation Syndrome Across Every Body System”

What Are Mast Cells and What Goes Wrong in MCAS?

Mast cells are immune sentinel cells positioned throughout your body, concentrated in tissues that interface with the outside world: skin, gut lining, respiratory tract, and around blood vessels and nerves. They are packed with granules containing over 200 chemical mediators, including histamine, tryptase, prostaglandins, leukotrienes, cytokines, and heparin [1].

In a healthy immune system, mast cells degranulate (release their contents) in response to genuine threats: parasitic infections, venom, tissue injury. In mast cell activation syndrome, these cells become hyperreactive. They degranulate in response to triggers that should not provoke an immune response: temperature changes, certain foods, stress, vibration, fragrances, or even exercise [2].

The result is a condition that can produce symptoms in virtually any organ system, at unpredictable times, with variable severity. This variability is a hallmark of MCAS and one reason it takes an average of 10 years from symptom onset to diagnosis.

MCAS vs. Mastocytosis: An Important Distinction

These two conditions are often confused but differ fundamentally:

• Mastocytosis involves a clonal proliferation of mast cells (there are literally too many of them). It is driven by mutations in the KIT gene (usually D816V) and can be detected by bone marrow biopsy. Systemic mastocytosis is relatively rare, affecting roughly 1 in 10,000 people [3].
• MCAS involves normal or near-normal numbers of mast cells that are hyperreactive. The problem is not quantity but behavior. MCAS is far more common than mastocytosis, though exact prevalence remains debated, with estimates suggesting it may affect up to 17% of the population in some form [4].

Treatment strategies overlap (both conditions respond to mast cell stabilizers and antihistamines), but the diagnostic workup and prognosis differ significantly.

Symptoms by Organ System

Skin

The skin is one of the most mast cell-dense tissues in the body, making skin symptoms among the most common and visible manifestations of MCAS:

• Flushing: Episodic redness, warmth, and sometimes burning of the face, neck, and chest. Flushing can last minutes to hours and is often triggered by heat, alcohol, stress, or spicy foods. It differs from normal blushing in its intensity, duration, and the burning quality that often accompanies it [5].
• Urticaria (hives): Raised, itchy welts that appear suddenly and may migrate across the body. In MCAS, hives can occur without any identifiable external allergen.
• Dermatographism: The ability to “write” on the skin with light pressure and have the marks remain as raised, red welts for minutes to hours. Present in roughly 5% of the general population but is significantly more common in MCAS.
• Pruritus (itching): Generalized itching without a rash. Can be severe enough to disrupt sleep.
• Angioedema: Deep swelling of the skin, often around the eyes, lips, or extremities. Unlike hives (which are superficial), angioedema involves deeper tissue layers and can be alarming when it affects the face.

Gastrointestinal

GI symptoms are present in 60-80% of MCAS patients and are frequently the most disabling [6]:

• Abdominal cramping and pain: Often episodic, sometimes severe, and not always related to meals.
• Nausea: Can be chronic and low-grade or sudden and intense. Sometimes accompanied by vomiting.
• Diarrhea: May be watery or loose, sometimes alternating with constipation. Histamine stimulates gastric acid secretion and increases intestinal motility.
• Bloating: Can be significant. The overlap with SIBO is real, as mast cell activation in the gut can impair motility and predispose to bacterial overgrowth.
• Gastroesophageal reflux: Histamine stimulates parietal cells to produce stomach acid via H2 receptors. Chronic acid overproduction from mast cell activation can cause persistent reflux that does not fully respond to standard PPI therapy.
• Food intolerances: Patients often report an expanding list of food sensitivities. This is not classical food allergy (IgE-mediated) but rather mast cell-mediated reactions to food components, particularly histamine-rich foods, salicylates, and certain additives.

Cardiovascular

• Tachycardia: Rapid heart rate, often postural (worse when standing). Histamine acts on H1 and H2 receptors in the heart to increase heart rate. The overlap with POTS is common and well-documented [7].
• Hypotension: Histamine causes vasodilation, which can drop blood pressure. Patients may feel lightheaded, dizzy, or faint, especially when standing.
• Presyncope and syncope: Near-fainting or actual fainting episodes during severe mast cell activation flares.
• Chest pain: Can result from coronary artery spasm (Kounis syndrome, a mast cell-mediated phenomenon) or from esophageal spasm triggered by mast cell mediators.

Neurological

• Brain fog: Difficulty concentrating, word-finding problems, and short-term memory impairment. This is one of the most commonly reported and most frustrating MCAS symptoms. Histamine is a neurotransmitter in the brain, and excess circulating histamine disrupts cognitive function [8].
• Headaches and migraines: Mast cells are abundant in the meninges (the membranes surrounding the brain). Their activation releases vasoactive mediators that can trigger migraine-like headaches.
• Anxiety and panic-like episodes: Histamine and other mast cell mediators can produce acute anxiety, a sense of impending doom, or full panic attacks. These episodes can be difficult to distinguish from primary anxiety disorders.
• Insomnia: Histamine promotes wakefulness (which is why antihistamines cause drowsiness). Excess histamine can disrupt sleep onset and maintenance.
• Peripheral neuropathy: Tingling, numbness, or burning sensations in the extremities.

Respiratory

• Nasal congestion and rhinitis: Chronic “allergies” that do not respond to typical allergy treatments. Nasal mast cells release histamine in response to irritants, temperature changes, or fragrances.
• Wheezing and shortness of breath: Mast cell mediators cause bronchoconstriction. Some MCAS patients carry an asthma diagnosis for years before MCAS is recognized.
• Throat tightness: A sensation of the throat closing or swelling. This can be alarming and may represent mild laryngeal angioedema.

Musculoskeletal

• Joint and muscle pain: Migratory aches and pains without inflammatory joint disease on testing.
• Bone pain: Mast cell mediators (particularly prostaglandins and cytokines) can cause deep bone aching.

Anaphylaxis and Severe Reactions

At its most extreme, MCAS can cause anaphylaxis or anaphylactoid reactions: sudden onset of hypotension, tachycardia, difficulty breathing, throat swelling, and sometimes loss of consciousness. In MCAS, these severe reactions can occur without a clear IgE-mediated trigger, which is confusing for both patients and emergency physicians [9]. Any patient with recurrent unexplained anaphylaxis should be evaluated for MCAS.

Common MCAS Triggers

One of the defining features of MCAS is that symptoms are triggered by stimuli that should not provoke mast cell degranulation. Common triggers include:

• Temperature extremes: Heat, cold, and rapid temperature changes
• Physical stimuli: Vibration, pressure, friction, exercise, and sunlight
• Emotional stress: Mast cells have receptors for corticotropin-releasing hormone (CRH), connecting them directly to the stress response [10]
• Foods: High-histamine foods (aged cheese, fermented foods, wine, cured meats), alcohol, certain food additives, and individual-specific triggers
• Fragrances and chemicals: Perfumes, cleaning products, paint fumes, and cigarette smoke
• Medications: NSAIDs, opioids, certain antibiotics (vancomycin, fluoroquinolones), contrast dyes, and some anesthetic agents
• Hormonal fluctuations: Many women with MCAS report symptom worsening around menstruation, ovulation, or during perimenopause. Estrogen upregulates mast cell activation.
• Infections: Viral and bacterial infections can trigger prolonged MCAS flares

The EDS-POTS-MCAS Triad

Clinicians working with connective tissue disorders have increasingly recognized a triad of co-occurring conditions: hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and MCAS. While the exact mechanism linking all three is still being studied, the overlap is striking [7].

One hypothesis involves connective tissue abnormalities in hEDS affecting the structural support around mast cells, making them mechanically unstable and more prone to degranulation. Mast cell mediators then contribute to autonomic dysfunction (POTS) through their effects on blood vessels and the nervous system. If you have been diagnosed with one of these three conditions and have unexplained symptoms in other systems, screening for the other two is reasonable.

How MCAS Is Diagnosed

The current consensus diagnostic criteria for MCAS require all three of the following [11]:

1. Episodic symptoms consistent with mast cell mediator release affecting two or more organ systems (skin, GI, cardiovascular, respiratory, neurological).
2. Laboratory evidence of mast cell mediator elevation during or shortly after a symptomatic episode. The most commonly tested markers are serum tryptase (a 20% + 2 ng/mL rise above baseline during an acute episode), 24-hour urine N-methylhistamine, urine prostaglandin D2, and urine leukotriene E4.
3. Symptom improvement with mast cell-targeted therapy (H1 antihistamines, H2 antihistamines, mast cell stabilizers, or leukotriene inhibitors).

In practice, meeting criterion 2 can be challenging. Mast cell mediators are rapidly cleared from the blood (tryptase half-life is about 2 hours), so blood samples drawn hours after a flare may come back normal. Urine testing over 24 hours is often more sensitive than a single blood draw [12].

Practical Diagnostic Tips

• Baseline tryptase should be drawn when you are at your symptom-free best. A second tryptase should be drawn during or within 1-4 hours of a significant flare.
• 24-hour urine collections for prostaglandin D2, N-methylhistamine, and leukotriene E4 should be done during a symptomatic period, not during a quiet phase.
• Avoid antihistamines for 48-72 hours before urine testing if safely possible (this may not be feasible for all patients).
• Refrigerate urine samples during collection (prostaglandins degrade at room temperature).

Symptom Tracking

Because MCAS symptoms wax and wane and involve multiple systems, a symptom diary is invaluable both for diagnosis and for identifying individual triggers. Track the following:

• Date, time, and duration of each symptom episode
• Which symptoms occurred and their severity (1-10 scale)
• Potential triggers: food intake, environmental exposures, stress, exercise, menstrual cycle timing, weather changes
• Medications taken and their effect on symptoms
• Sleep quality the night before

After 4-6 weeks of tracking, patterns often emerge that are not apparent when symptoms feel random. Many patients discover that their “random” flares actually correlate with specific triggers, hormonal cycles, or cumulative stress loads [13].

When to Seek Evaluation

Consider MCAS evaluation if you have:

• Symptoms spanning two or more organ systems without another clear diagnosis
• Recurrent “allergic” reactions without identifiable IgE-mediated allergies
• Unexplained anaphylaxis or anaphylactoid episodes
• A growing list of food and environmental sensitivities
• A diagnosis of hEDS or POTS with additional unexplained symptoms
• Chronic symptoms that fluctuate in severity and seem to worsen with heat, stress, or certain foods

MCAS-literate allergists, immunologists, and integrative medicine physicians are the most experienced with diagnosis and management. Given the multi-system nature of MCAS, many patients have seen multiple specialists before someone connects the dots.

Related Reading

• Mast Cell Activation Syndrome: Complete Guide

References

1. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163-172. doi:10.1056/NEJMra1409760
2. Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349-355. doi:10.1016/j.jaci.2017.06.007
3. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427. doi:10.1182/blood-2016-09-731893
4. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10
5. Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther. 2013;35(5):548-562. doi:10.1016/j.clinthera.2013.04.001
6. Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1):147-152.e2. doi:10.1016/j.jaci.2011.04.037
7. Kohn A, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273-297. doi:10.1007/s12016-019-08755-8
8. Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207-215. doi:10.1016/j.amjms.2016.12.013
9. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099-1104.e4. doi:10.1016/j.jaci.2010.08.035
10. Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015;9:225. doi:10.3389/fnins.2015.00225
11. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.e1. doi:10.1016/j.jaip.2019.01.006
12. Vysniauskaite M, Hertfelder HJ, Oldenburg J, et al. Determination of plasma heparin level improves identification of systemic mast cell activation disease. PLoS One. 2015;10(4):e0124912. doi:10.1371/journal.pone.0124912
13. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis (Berl). 2021;8(2):137-152. doi:10.1515/dx-2020-0005